|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2012. CA Cancer J Clin.
62:283–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cho KR and Shih IeM: Ovarian cancer. Annu
Rev Pathol. 4:287–313. 2009. View Article : Google Scholar :
|
|
3
|
Mandai M, Matsumura N, Baba T, Yamaguchi
K, Hamanishi J and Konishi I: Ovarian clear cell carcinoma as a
stress-responsive cancer: Influence of the microenvironment on the
carcinogenesis and cancer phenotype. Cancer Lett. 310:129–133.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shimizu S, Kanaseki T, Mizushima N, Mizuta
T, Arakawa-Kobayashi S, Thompson CB and Tsujimoto Y: Role of Bcl-2
family proteins in a non-apoptotic programmed cell death dependent
on autophagy genes. Nat Cell Biol. 6:1221–1228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rashmi R, Pillai SG, Vijayalingam S,
Ryerse J and Chinnadurai G: BH3-only protein BIK induces
caspase-independent cell death with autophagic features in Bcl-2
null cells. Oncogene. 27:1366–1375. 2008. View Article : Google Scholar
|
|
7
|
Furuya D, Tsuji N, Yagihashi A and
Watanabe N: Beclin 1 augmented cis-diamminedichloroplatinum induced
apoptosis via enhancing caspase-9 activity. Exp Cell Res.
307:26–40. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun Y, Liu JH, Jin L, Pan L, Sui YX, Yang
Y and Shi H: Beclin 1 influences cisplatin-induced apoptosis in
cervical cancer CaSki cells by mitochondrial dependent pathway. Int
J Gynecol Cancer. 22:1118–1124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J: Beclin 1 bridges autophagy,
apoptosis and differentiation. Autophagy. 4:947–948. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eskelinen EL and Saftig P: Autophagy: A
lysosomal degradation pathway with a central role in health and
disease. Biochim Biophys Acta. 1793:664–673. 2009. View Article : Google Scholar
|
|
11
|
Katagiri A, Nakayama K, Rahman MT, Rahman
M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K,
Kobayashi H, et al: Loss of ARID1A expression is related to shorter
progression-free survival and chemoresistance in ovarian clear cell
carcinoma. Mod Pathol. 25:282–288. 2012.
|
|
12
|
Rahman M, Nakayama K, Rahman MT, Nakayama
N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM,
et al: Clinicopathologic and biological analysis of PIK3CA mutation
in ovarian clear cell carcinoma. Hum Pathol. 43:2197–2206. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rahman MT, Nakayama K, Rahman M, Nakayama
N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM,
et al: Prognostic and therapeutic impact of the chromosome 20q13.2
ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer.
118:2846–2857. 2012. View Article : Google Scholar
|
|
14
|
Nakayama K, Nakayama N, Jinawath N, Salani
R, Kurman RJ, Shih IeM and Wang TL: Amplicon profiles in ovarian
serous carcinomas. Int J Cancer. 120:2613–2617. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakayama K, Miyazaki K, Kanzaki A,
Fukumoto M and Takebayashi Y: Expression and cisplatin sensitivity
of copper-transporting P-type adenosine triphosphatase (ATP7B) in
human solid carcinoma cell lines. Oncol Rep. 8:1285–1287.
2001.PubMed/NCBI
|
|
16
|
Wu H, Zhu H, Liu DX, Niu TK, Ren X, Patel
R, Hait WN and Yang JM: Silencing of elongation factor-2 kinase
potentiates the effect of 2-deoxy-D-glucose against human glioma
cells through blunting of autophagy. Cancer Res. 69:2453–2460.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng Y, Li H, Ren X, Niu T, Hait WN and
Yang J: Cytoprotective effect of the elongation factor-2
kinase-mediated autophagy in breast cancer cells subjected to
growth factor inhibition. PLoS One. 5:e97152010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schwartz DR, Kardia SL, Shedden KA, Kuick
R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, et
al: Gene expression in ovarian cancer reflects both morphology and
biological behavior, distinguishing clear cell from other
poor-prognosis ovarian carcinomas. Cancer Res. 62:4722–4729.
2002.PubMed/NCBI
|
|
19
|
Yamaguchi K, Mandai M, Oura T, Matsumura
N, Hamanishi J, Baba T, Matsui S, Murphy SK and Konishi I:
Identification of an ovarian clear cell carcinoma gene signature
that reflects inherent disease biology and the carcinogenic
processes. Oncogene. 29:1741–1752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sugiyama T, Kamura T, Kigawa J, Terakawa
N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical
characteristics of clear cell carcinoma of the ovary: A distinct
histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goff BA, Sainz de la Cuesta R, Muntz HG,
Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer
BE, et al: Clear cell carcinoma of the ovary: A distinct histologic
type with poor prognosis and resistance to platinum-based
chemotherapy in stage III disease. Gynecol Oncol. 60:412–417. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Köbel M, Xu H, Bourne PA, Spaulding BO,
Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, et
al: IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis
in ovarian carcinoma of clear cell subtype. Mod Pathol. 22:469–475.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ho CM, Cheng WF, Lin MC, Chen TC, Huang
SH, Liu FS, Chien CC, Yu MH, Wang TY and Hsieh CY: Prognostic and
predictive values of E-cadherin for patients of ovarian clear cell
adenocarcinoma. Int J Gynecol Cancer. 20:1490–1497. 2010.PubMed/NCBI
|
|
24
|
Díaz-Montes TP and Bristow RE: Secondary
cytoreduction for patients with recurrent ovarian cancer. Curr
Oncol Rep. 7:451–458. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harter P and du Bois A: The role of
surgery in ovarian cancer with special emphasis on cytoreductive
surgery for recurrence. Curr Opin Oncol. 17:505–514. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gadducci A, Iacconi P, Cosio S, Fanucchi
A, Cristofani R and Genazzani AR: Complete salvage surgical
cytoreduction improves further survival of patients with late
recurrent ovarian cancer. Gynecol Oncol. 79:344–349. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gadducci A, Iacconi P, Fanucchi A, Cosio
S, Teti G and Genazzani AR: Surgical cytoreduction during
second-look laparotomy in patients with advanced ovarian cancer.
Anticancer Res. 20:1959–1964. 2000.PubMed/NCBI
|
|
28
|
Zang RY, Li ZT, Tang J, Cheng X, Cai SM,
Zhang ZY and Teng NN: Secondary cytoreductive surgery for patients
with relapsed epithelial ovarian carcinoma: Who benefits? Cancer.
100:1152–1161. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liang XH, Jackson S, Seaman M, Brown K,
Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and
inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aita VM, Liang XH, Murty VV, Pincus DL, Yu
W, Cayanis E, Kalachikov S, Gilliam TC and Levine B: Cloning and
genomic organization of beclin 1, a candidate tumor suppressor gene
on chromosome 17q21. Genomics. 59:59–65. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh
H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al:
Promotion of tumorigenesis by heterozygous disruption of the beclin
1 autophagy gene. J Clin Invest. 112:1809–1820. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yue Z, Jin S, Yang C, Levine AJ and Heintz
N: Beclin 1, an autophagy gene essential for early embryonic
development, is a haploinsufficient tumor suppressor. Proc Natl
Acad Sci USA. 100:15077–15082. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mariño G, Salvador-Montoliu N, Fueyo A,
Knecht E, Mizushima N and López-Otín C: Tissue-specific autophagy
alterations and increased tumorigenesis in mice deficient in
Atg4C/autophagin-3. J Biol Chem. 282:18573–18583. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Karantza-Wadsworth V, Patel S, Kravchuk O,
Chen G, Mathew R, Jin S and White E: Autophagy mitigates metabolic
stress and genome damage in mammary tumorigenesis. Genes Dev.
21:1621–1635. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mathew R, Kongara S, Beaudoin B, Karp CM,
Bray K, Degenhardt K, Chen G, Jin S and White E: Autophagy
suppresses tumor progression by limiting chromosomal instability.
Genes Dev. 21:1367–1381. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kuo KT, Mao TL, Jones S, Veras E, Ayhan A,
Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, et al: Frequent
activating mutations of PIK3CA in ovarian clear cell carcinoma. Am
J Pathol. 174:1597–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jones S, Wang TL, Shih IeM, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
